Press release: Abalone Bio and PipeBio announce collaboration

PipeBio’s integrated bioinformatics platform supports Abalone Bio’s antibody drug discovery efforts

Press release
October 25, 2022
Read time:
An image showing the logo of PipeBio and Abalone Bio together with the announcement of Abalone Bio's and PipeBio's collaboration on October 25th 2022

PipeBio’s integrated bioinformatics platform supports Abalone Bio’s antibody drug discovery efforts to target difficult membrane proteins and enable modulation of previously inaccessible anti-cancer or anti-inflammatory activities


Abalone Bio, a preclinical biotherapeutics company and PipeBio, a bioinformatics cloud platform provider, announce their continued collaboration around antibody bioinformatics analysis supporting Abalone Bio’s antibody discovery research and development efforts. PipeBio’s advanced bioinformatic platform complements Abalone Bio’s Functional Antibody Selection Technology (FAST) antibody discovery platform, which aims to find treatments for difficult-to-drug G-protein coupled receptor (GPCR) and ion channel targets with disease indications ranging from inflammatory diseases, kidney and liver diseases, immuno-oncology to diabetes and obesity.

Since implementation, the bioinformatics platform from PipeBio has helped Abalone Bio transition into large scale NGS data analysis of antibodies, with single-click analysis pipelines helping Abalone Bio speed up analysis and quickly identify candidate antibody sequences for further development.

PipeBio’s workflow is easy to use for members of our team across the full range of computational experience, making NGS-based antibody library and enrichment analyses accessible while still remaining powerful and flexible.

Richard Yu, CEO and co-founder, Abalone Bio

In addition to a number of promising preclinical programs, Abalone Bio’s pursuit of GPCR-modulating antibody therapeutics includes several discovery programs where PipeBio’s bioinformatics cloud is utilized for data storage, computation and advanced data analysis. As part of the collaboration, PipeBio has provided bespoke graphics solutions for estimation of antibody library diversity, which have been widely adopted and employed by Abalone Bio.

We are thrilled to support Abalone Bio’s research efforts with both our tools and expertise. For us, the most exciting part is to be able to contribute to novel therapeutics for the wide array of diseases that Abalone Bio’s GPCR-targeting research approach intends to address.”

Jannick Bendtsen, CEO, PipeBio

About Abalone Bio

Abalone Bio combines synthetic biology and data-driven computation to identify antibody drugs that activate and modulate difficult membrane protein targets, which enables access to previously inaccessible therapeutic biological activities such as novel anti-cancer or anti-inflammatory activities.

Contact information

Richard Yu, CEO

About PipeBio

PipeBio is a rapidly growing cloud-based bioinformatics platform with presence in Europe and the Americas. Teams in pharma, biotechs and academia use PipeBio to quickly characterize and develop better lead candidates. The strength of PipeBio is its unique ability to make structured sequence and assay data easily accessible to scientists, bioinformaticians and managers, combined with an ever growing suite of powerful analysis tools.

Contact information

Jannick Bendtsen
Access PipeBio’s Press kit


Right-pointing black chevron

Link to original press release on PRWeb.

Sign up for a free trial now

Other recent posts